Even prior to the ORAL Surveillance, concerning safety signals appeared during the trials of BARI regarding increased risk of venous thromboembolism (VTE) suggesting a possible class effect of JAK inhibitors, rather than a risk associated solely with TOFA and strong JAK1/JAK3 inhibition [8]. This evidence concerns the gene JAK1 and venous thromboembolism.